Rolipram attenuates bleomycin A5-induced pulmonary fibrosis in rats
Jin Bing PAN,
Yu Hong HOU,
Guo Jun ZHANG,
Jin Bing PAN
Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University,
Department of Respiratory Medicine, Henan Provincial People's Hospital,
Search for more papers by this authorYu Hong HOU
Department of Emergency Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Search for more papers by this authorCorresponding Author
Guo Jun ZHANG
Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University,
Guo Jun Zhang, Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University, 1 JianShe Road, Zhengzhou 450053, China. Email: [email protected]Search for more papers by this authorJin Bing PAN,
Yu Hong HOU,
Guo Jun ZHANG,
Jin Bing PAN
Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University,
Department of Respiratory Medicine, Henan Provincial People's Hospital,
Search for more papers by this authorYu Hong HOU
Department of Emergency Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Search for more papers by this authorCorresponding Author
Guo Jun ZHANG
Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University,
Guo Jun Zhang, Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University, 1 JianShe Road, Zhengzhou 450053, China. Email: [email protected]Search for more papers by this authorABSTRACT
Background and objective: Pulmonary fibrosis has a poor prognosis. The pathogenesis of fibrotic disorders is unclear, but the extent of lung damage due to persistent inflammation is regarded as a critical factor. Rolipram inhibits inflammation induced by various stimuli, as well as the chemotaxis of fibroblasts. In this study rolipram was used to treat pulmonary fibrosis induced by bleomycin A5 in rats, and the possible mechanisms were investigated.
Methods: Rolipram (0.25 mg/kg) was administered intraperitoneally daily, following intratracheal instillation of bleomycin A5 (5 mg/kg). Animals were killed at 7 or 28 days after bleomycin A5 instillation, and indices of lung damage and fibrosis were evaluated.
Results: Bleomycin A5 induced pulmonary inflammation and fibrosis, increased the levels of malondialdehyde and tumour necrosis factor-α and enhanced accumulation of collagen in the lungs. Rolipram administration significantly attenuated these effects.
Conclusions: Rolipram ameliorated pulmonary inflammation and fibrosis induced by bleomycin A5 in rats. The effects of rolipram may be associated with its antioxidant activity and inhibition of tumour necrosis factor-α production.
REFERENCES
- 1 Lagente V, Manoury B, Nénan S, Le Quément C, Martin-Chouly C et al. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Braz. J. Med. Biol. Res. 2005; 38: 1521–30.
- 2 Smith RE, Strieter RM, Phan SH, Lukacs N, Kunkel SL. TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. J. Leukoc. Biol. 1998; 64: 528–36.
- 3 Kroegel C, Mock B, Hengst U, Reissig A. Interferon-gamma-1b: therapeutic option in advanced idiopathic pulmonary fibrosis? Respiration 2004; 71: 656–7.
- 4 Giri SN. Novel pharmacological approaches to manage interstitial lung fibrosis in the twenty-first century. Annu. Rev. Pharmacol. Toxicol. 2003; 43: 73–95.
- 5 Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001; 134: 136–51.
- 6 Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J. Rare Dis. 2008; 3: 8.
- 7 Lagente V, Moodley I, Perrin S, Mottin G, Junien JL. Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. Eur. J. Pharmacol. 1994; 255: 253–6.
- 8 Lagente V, Pruniaux MP, Junien JL, Moodley I. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am. J. Respir. Crit. Care Med. 1995; 151: 1720–4.
- 9 Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE) 4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci. 1997; 18: 164–71.
- 10 Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am. J. Respir. Cell Mol. Biol. 2002; 26: 694–701.
- 11 Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C et al. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci. 2004; 75: 823–40.
- 12 Katzenstein A-L, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 1998; 157: 1301–15.
- 13 Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am. J. Respir. Cell Mol. Biol. 2005; 33: 9–13.
- 14 Snider GL, Celli BR, Goldstein RH, O'Brien JJ, Lucey EC. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Am. Rev. Respir. Dis. 1978; 117: 289–97.
- 15 Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004; 59: 31–8.
- 16 Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW, Crystal RG. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am. Rev. Respir. Dis. 1979; 120: 893–9.
- 17 Piguet PF. Cytokines involved in pulmonary fibrosis. Int. Rev. Exp. Pathol. 1993; 34: 173–81.
- 18 Keane MP, Strieter RM, Belperio JA. Mechanisms and mediators of pulmonary fibrosis. Crit. Rev. Immunol. 2005; 25: 429–63.
- 19 Noble PW, Jiang D. Matrix regulation of lung injury, inflammation, and repair: the role of innate immunity. Proc. Am. Thorac. Soc. 2006; 3: 401–4.
- 20 Schudt C, Tenor H, Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J. 1995; 8: 1179–83.
- 21 Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid. Redox Signal. 2008; 10: 287–301.
- 22 Armstrong RA. Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br. J. Pharmacol. 1995; 116: 2903–8.
- 23 Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br. J. Pharmacol. 2006; 147: S252–7.
- 24 Barnette MS. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog. Drug Res. 1999; 53: 193–229.
- 25 Spina D. The potential of PDE4 inhibitors in asthma or COPD. Curr. Opin. Investig. Drugs 2000; 1: 204–13.
- 26 Rainsford KD, Ying C, Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. J. Pharm. Pharmacol. 1996; 48: 46–52.
- 27 Nash JR, McLaughlin PJ, Butcher D, Corrin B. Expression of tumor necrosis factor-alpha in cryptogenic fibrosing alveolitis. Histopathology 1993; 22: 343–7.
- 28 Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 1995; 96: 250–9.
- 29 Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am. J. Respir. Cell Mol. Biol. 2005; 32: 342–9.
- 30 Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. 1989; 170: 655–63.
- 31 Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA et al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J. Pharmacol. Exp. Ther. 1998; 287: 705–11.
- 32 Corbel M, Belleguic C, Boichot E, Lagente V. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol. Toxicol. 2002; 18: 51–61.
- 33 Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer. Br. J. Pharmacol. 1996; 118: 649–58.
- 34 Gonçalves de Moraes VL, Singer M, Vargaftig BB, Chignard M. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br. J. Pharmacol. 1998; 123: 631–6.
- 35 Ouaged M, Martin-Chouly CAE, Leportier C, Belleguic C, Delaval P et al. The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNF-alpha production in whole blood of COPD patients. Fund. Clin. Pharmacol. 2002; 16: 369.
- 36 Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am. J. Pathol. 1991; 138: 1257–65.
- 37 Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002; 122: S286–9.
- 38 Houslay MD, Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem. Sci. 1997; 22: 217–24.
- 39 Kohyama T, Ertl RF, Valenti V, Spurzem J, Kawamoto M et al. Prostaglandin E2 inhibits fibroblast chemotaxis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001; 281: L1257–63.
- 40 Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur. J. Pharmacol. 2007; 572: 12–22.
- 41 Lindenschmidt RC, Witschi H. Attenuation of pulmonary fibrosis in mice by aminophylline. Biochem. Pharmacol. 1985; 34: 4269–73.
- 42 Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008; 294: L24–33.
